valu usd unless otherwis note
result guidanc reflect
view increas guidanc organ revenu growth
second time row follow anoth strong quarter believ
room upward revis depth matur
mdt pipelin review earn call increas confid
level organ revenu growth possibl rais
estim reiter outperform rate price target
mitg rtg diabet segment deliv upsid revenu
estim ww revenu estim
exclud fx organ growth exceed guidanc
wide margin within mitg posit surpris came
respiratori gastrointestin renal recent result
led us reduc estim busi pain therapi
expect specialti therapi less sourc upsid
pain therapi intelli respons ww growth
spinal cord stimul busi continu captur share
dg y/i train user base minim continu
grow sequenti
revis revenu guidanc room upsid forecast
organ revenu growth higher end bp
prior guidanc impli revenu includ fx close
guidanc yield forecast organ growth
comp tougher believ growth realist given
magnitud posit surpris new product flow
expect ep guidanc chang tariff
chines import dilut mzor acquisit expect
close absorb upsid better oper
perform new estim prior
ebit margin forecast achiev forecast
ebit margin cc would increas bp actual figur
bp lay rest investor concern guid
bp cc might risk improv
sg line compani continu invest advanc
pipelin see earli benefit enterpris excel
program commenc januari
pipelin review support estim organ growth
come market soon valiant navion thorac stent graft system
apv western europ crt-p azur pacemak crhf
 stealth react cathet riptid aspir system rtg
minim dg ex-u new product
re-affirmed launch robotic-assist surgeri platform
estim organ
dissemin produc price prior trade day market close estimate unless otherwis note
forecast least organ growth cvg
rtg mitg expect grow around
diabet group higher rate believ around
guidanc impli ww revenu close
requir addit year estim
therapi innov contribut approxim half
revenu growth balanc come global expans
especi emerg market value-bas health care
tavr micra reveal linq remain key growth
driver cvg five high-growth market within cvg
tavr diagnost mid-teen follow endoven
atrial fibril lvad high single-digit low double-
digit plan introduc largest valv
size evolut mm th potenti low-risk
indic enhanc micra convert dual-
chamber devic significantli expand potenti market
next-gener icm reveal linq also schedul
launch beyond
double-digit growth emerg market expect
continu em revenu increas
compris ww revenu forti percent em
revenu came greater china middl east
africa latin america switch indirect
direct distribut major impact em growth
margin also made infrastructur invest key
market enabl market access improv penetr
oper margin target appear realist lower
goal annual improv bp
bp increas everi year june investor
day enterpris excel program lie heart
achiev target accordingli ep growth target
also come cc includ modest
currenc volatil reason move away cc
ep guidanc fx exposur fulli hedg
sever currenc especi emerg market
becom larger compon revenu
bloomberg capit market estim upside/downside/target
price target base price-to-earnings multipl
ep y/i mdt current price-to-earnings multipl
ep estim around key assumpt
underli ep estim organ growth
least growth basi point
oper margin expans fiscal year excess
free cash flow dividend deploy primarili
share buy-back target price-to-earnings price-to-earnings
ntm averag share
upsid scenario base price-to-earnings multipl
cy ep key assumpt underli
ep estim revenu growth
achiev combin accret
superior perform key product categori tavr
leadless pace neurovascular neurosurgeri diabet
surgic innov basi point oper
margin expans
downsid scenario base price-to-earnings multipl
cy ep key assumpt underli ep
estim revenu growth
basi point oper margin expans
meaning share buy-back
exhibit revenu contribut segment geographi
exhibit revenu guidanc
geographi worldwidegeographi internationalgeographi worldwiderevenu revenu growth y/ycontribut revenu growth intenational cardiac vascular vascular rhythm heart rhythm heart structur heart structur heart peripher peripher invas therapi invas therapi gastrointestin gastrointestin therapi therapi growth growth intenational excl revenu growth revenu end revenu high end revenu y/yrevenu exhibit revenu model
exhibit price-to-earnings ntm last five year base consensu estim
geographi worldwidegeographi internationalgeographi worldwiderevenu pro-forma revenu growth y/ycontribut revenu growth intenational cardiac vascular vascular rhythm heart rhythm heart structur heart structur heart peripher peripher invas therapi invas therapi gastrointestin gastrointestin therapi therapi growth growth intenational excl revenu growth revenu price-to-earnings ntm medic suppli devic
exhibit result versu estim
price target base ep estim y/i mdt
current price-to-earnings multipl ep estim compar target multipl key
assumpt underli ep estim organ growth least
growth basi point oper margin expans
compani realiz benefit enterpris excel program place
excess free cash flow dividend deploy primarili share buy-back
price target basi outperform rate
risk rate price target
lacklust growth key franchis includ pace defibril system atrial
fibril tavr drug-elut stent surgic innov brain pain therapi spine
inabl achiev target cost save manag believ achiev billion
gross save end enterpris excel program
project save fail materi ep estim could risk
risk price target rate includ potenti regulatori delay reject
failur devic clinic trial weaken demand key market price pressur weak
util trend fx
lead world-wide medic technolog compani engag manufactur
sell device-bas medic therapi compani oper four segment cardiac
vascular group restor therapi group diabet group minim invas
million except ep fy april
interest expens net
